Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
McKinsey
Fuji
Federal Trade Commission
Fish and Richardson
Baxter
Teva
McKesson

Generated: April 20, 2018

DrugPatentWatch Database Preview

Abbvie Company Profile

« Back to Dashboard

Summary for Abbvie
International Patents:1284
US Patents:81
Tradenames:77
Ingredients:64
NDAs:89
Drug Master File Entries: 1

Drugs and US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie NITROPRESS sodium nitroprusside INJECTABLE;INJECTION 018450-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-003 Oct 22, 1996 AB RX Yes No ➤ Sign Up ➤ Sign Up
Abbvie TRILIPIX choline fenofibrate CAPSULE, DELAYED RELEASE;ORAL 022224-002 Dec 15, 2008 AB RX Yes Yes 7,259,186 ➤ Sign Up Y ➤ Sign Up
Abbvie KALETRA lopinavir; ritonavir SOLUTION;ORAL 021251-001 Sep 15, 2000 AA RX Yes Yes 6,911,214*PED ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Abbvie

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TRICOR fenofibrate TABLET;ORAL 021656-001 Nov 5, 2004 5,145,684 ➤ Sign Up
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 6,406,715 ➤ Sign Up
Abbvie Endocrine Inc LUPRON DEPOT leuprolide acetate INJECTABLE;INJECTION 020011-001 Oct 22, 1990 5,480,656 ➤ Sign Up
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 6,080,428 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial ➤ Subscribe 2009-08-04
➤ Subscribe Extended-release Tablets 250 mg ➤ Subscribe 2004-05-03
➤ Subscribe Delayed-release Capsules 45 mg ➤ Subscribe 2009-09-02
➤ Subscribe Tablets 48 mg ➤ Subscribe 2008-07-01
➤ Subscribe Tablets 400 mg and 600 mg ➤ Subscribe 2010-05-10
➤ Subscribe Tablets 2.5 mg/200 mg ➤ Subscribe 2006-02-24
➤ Subscribe Tablets 100 mg ➤ Subscribe 2010-12-21
➤ Subscribe Tablets 100 mg/25 mg ➤ Subscribe 2008-12-23
➤ Subscribe Capsules 100 mg ➤ Subscribe 2012-10-31
➤ Subscribe Capsules 1 mcg and 2 mcg ➤ Subscribe 2008-10-14
➤ Subscribe Oral Solution 80 mg/20 mg per mL ➤ Subscribe 2014-06-19
➤ Subscribe Gel Metered-dose Pump 1% ➤ Subscribe 2008-12-19
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 2007-11-09
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 2007-07-24
➤ Subscribe Injection 2 mg/mL, 10 mL vial ➤ Subscribe 2009-08-12
➤ Subscribe Extended-release Tablets 500 mg ➤ Subscribe 2005-02-08
➤ Subscribe Delayed-release Capsules 135 mg ➤ Subscribe 2009-09-01
➤ Subscribe Tablets 145 mg ➤ Subscribe 2007-10-19
➤ Subscribe Extended-release Tablet 500 mg ➤ Subscribe 2010-12-06
➤ Subscribe Tablets 5 mg/200 mg ➤ Subscribe 2005-05-27
➤ Subscribe Gel 1.62% ➤ Subscribe 2012-04-06
➤ Subscribe Injection 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials ➤ Subscribe 2008-11-28
➤ Subscribe Gel 1.62% (1.25 g and 2.5 g packets) ➤ Subscribe 2013-06-19
➤ Subscribe Capsules 4 mcg ➤ Subscribe 2008-08-25
➤ Subscribe Tablets 1 mg, 2 mg and 4 mg ➤ Subscribe 2004-10-04
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2008-02-20

Non-Orange Book US Patents for Abbvie

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,452,194 Methods for treating HCV ➤ Sign Up
6,558,679 Container for an inhalation anesthetic ➤ Sign Up
8,193,367 Polymorph of a pharmaceutical ➤ Sign Up
6,596,317 Fenofibrate pharmaceutical composition having high bioavailability and method for preparing it ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Abbvie Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/010 United Kingdom ➤ Sign Up PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
C0016 France ➤ Sign Up PRODUCT NAME: OMBITASVIR DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/14/982 20150119
C/GB06/021 United Kingdom ➤ Sign Up PRODUCT NAME: PEGAPTANIB, PREFERABLY IN THE FORM OF ITS SODIUM SALT; REGISTERED: UK EU/1/05/325/001 20060201
0901 Netherlands ➤ Sign Up PRODUCT NAME: PIBRENTASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/17/1213 20170728
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
AstraZeneca
Teva
McKinsey
Cerilliant
US Department of Justice
Chubb
Medtronic
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.